上皮性卵巢癌中TGF-β1的表达与耐药相关基因的关系

发布时间：2018-05-15 21:44

本文选题：上皮性卵巢癌 + 转化生长因子　；参考：《河北医科大学》2015年硕士论文

【摘要】：目的:通过检测上皮性卵巢癌中TGF-β1的表达,分析TGF-β1与MDR1、PTEN、TOPOII、ERCC1、LIVIN耐药相关基因的相关性,筛选出与TGF-β1相关的耐药基因,希望通过多基因联合检测更客观全面的指导临床用药,降低耐药性,提高患者生存率,TGF-β1将成为卵巢癌耐药的分子标记及治疗的新靶点。方法:采用免疫组化方法分别检测TGF-β1在上皮性卵巢癌组(50例)、卵巢良性肿瘤组(20例)、正常卵巢组(20例)的表达情况,回顾分析相应组织切片中MDR1、PTEN、TOPOII、ERCC1、LIVIN耐药相关基因与TGF-β1的表达相关性,统计软件选用SPSS19.0,计数资料应用χ2检验,采用Spearman等级相关进行相关性分析,均以P0.05表示差异具有统计学意义。结果:1 TGF-β1在上皮性卵巢癌中的表达TGF-β1阳性表达主要定位于细胞浆,呈棕黄色颗粒染色。在20例正常卵巢组中TGF-β1有4例呈现出阳性表达,阳性表达率为20%(4/20例);在20例卵巢良性肿瘤组中TGF-β1有8例呈现出阳性表达,阳性表达率为40%(8/20例);在50例上皮性卵巢癌组中TGF-β1有38例呈现出阳性表达,阳性表达率为76%(38/50例);TGF-β1的阳性表达率在逐步上升。上皮性卵巢癌组TGF-β1的表达与正常卵巢组TGF-β1的表达进行比较,差异有显著性,具有统计学意义(P0.05);上皮性卵巢癌组TGF-β1的表达与卵巢良性肿瘤组TGF-β1的表达进行比较,差异有统计学意义(P0.05);正常卵巢组TGF-β1的表达与卵巢良性肿瘤组TGF-β1的表达进行比较,差异无统计学意义(P0.05)。2上皮性卵巢癌组织中TGF-β1的表达与临床病理特性的关系2.1年龄在28例年龄≥50岁的卵巢上皮性癌组织中TGF-β1阳性表达率为78.5%(22/28),在22例年龄50岁的卵巢上皮性癌组织中的TGF-β1阳性表达率为72.7%(16/22),二者比较差异无统计学意义(χ2=0.231,P0.05)2.2分期在34例Ⅲ-Ⅳ期卵巢癌中TGF-β1阳性表达率88.2%(30/34),16例Ⅰ期-Ⅱ期卵巢癌中TGF-β1阳性表达率50.0%(8/16),两者比较差异有统计学意义(χ2=8.720,P0.05)2.3组织学类型在24例浆液性囊腺癌中TGF-β1阳性表达率79.2%(19/24),16例粘液性囊腺癌中TGF-β1阳性表达率68.8%(11/16),10例卵巢子宫内膜样癌中TGF-β1阳性表达率80.0%(8/10),三者之间比较差异无统计学意义(χ2=0.739,P0.05);2.4组织病理分化程度在24例高中分化组中TGF-β1阳性表达率66.7%(16/24例),26例低分化组中TGF-β1阳性表达率84.6%(22/26例),二者比较差异无统计学意义(χ2=2.204,P0.05)。2.5淋巴结转移在32例淋巴结有转移组中TGF-β1阳性表达率81.3%(26/32例),18例有淋巴结无转移组中TGF-β1阳性表达率66.7%(12/18例),二者比较差异无统计学意义(χ2=0.663,P0.05)。3 TGF-β1的表达与MDR1、PTEN、TOPOII、ERCC1、LIVIN耐药相关基因的关系TGF-β1与MDR1两者的表达具有正相关性(r=0.322,P0.05)。TGF-β1与PTEN两者的表达具有负相关性(r=-0.668,P0.05)。TGF-β1与TOPOII两者的表达无相关性(r=-0.506,P=0.078)。TGF-β1与ERCC1两者的表达无相关性(r=-0.037,P=0.636)。TGF-β1与LIVIN两者的表达无相关性(r=-0.801,P=0.21)。结论:1 TGF-β1在上皮性卵巢癌中阳性表达水平很高,卵巢良性肿瘤和正常卵巢TGF-β1阳性表达水平都比上皮性卵巢癌低,正常卵巢组织、卵巢良性肿瘤、上皮性卵巢癌,TGF-β1的表达情况呈逐渐升高趋势,表明TGF-β1在卵巢组织由良性向恶性发展的过程中起了重要作用,TGF-β1可作为诊断上皮性卵巢癌的生物学指标。2卵巢癌组织中TGF-β1的表达与患者年龄大小、组织学的类型、组织病理分化程度、是否出现淋巴结转移无相关性,而与临床分期呈现正相关性。表明TGF-β1与卵巢癌的疾病进展相关。3上皮性卵巢癌中TGF-β1与MDR1的表达呈正相关,提示其在肿瘤的发生、发展中具有相互协同作用。TGF-β1与PTEN的表达呈负相关,说明其与PTEN相互拮抗。
[Abstract]:Objective: to determine the correlation between TGF- beta 1 and MDR1, PTEN, TOPOII, ERCC1, LIVIN resistance related genes, and to screen out the resistance genes related to TGF- beta 1 by detecting the expression of TGF- beta 1 in epithelial ovarian cancer, and to select the drug resistant genes related to TGF- beta 1. Methods: the expression of TGF- beta 1 in epithelial ovarian cancer group (50 cases), ovarian benign tumor group (20 cases) and normal ovarian group (20 cases) were detected by immunohistochemical method. The expression of MDR1, PTEN, TOPOII, ERCC1, LIVIN resistance related genes and the expression of TGF- beta 1 in the corresponding tissue sections were analyzed. Correlation, the statistical software was selected by SPSS19.0, the count data were tested by chi 2, and the correlation analysis of Spearman grade was used to analyze the correlation. The difference was statistically significant by P0.05. Results: the expression of 1 TGF- beta 1 in epithelial ovarian cancer was mainly located in the cytoplasm and stained with brown yellow granules, in 20 normal ovarian groups. In TGF- beta 1, 4 cases showed positive expression, positive expression rate was 20% (4/20 cases), and 8 cases of TGF- beta 1 in 20 cases of ovarian benign tumor showed positive expression, the positive expression rate was 40% (8/20 cases); in 50 cases of epithelial ovarian cancer, 38 cases of TGF- beta 1 showed positive expression, the positive expression rate was 76% (38/50 cases); the positive expression rate of TGF- beta 1 The expression of TGF- beta 1 in the epithelial ovarian cancer group was compared with the expression of TGF- beta 1 in the normal ovarian group, and the difference was statistically significant (P0.05). The expression of TGF- beta 1 in the epithelial ovarian cancer group was compared with the expression of TGF- beta 1 in the benign ovarian tumor group (P0.05); the expression of TGF- beta 1 in the normal ovarian group was the expression of TGF- beta 1. Compared with the expression of TGF- beta 1 in the benign ovarian tumor group, the difference was not statistically significant (P0.05), the relationship between the expression of TGF- beta 1 and the clinicopathological characteristics in the epithelial ovarian cancer tissue of.2 2.1 age was 78.5% (22/28) in 28 cases of ovarian epithelial carcinoma with age 50 years old (78.5% (22/28), and in 22 cases of ovarian epithelial carcinoma, age 50 years old. The positive expression rate of TGF- beta 1 in the tissue was 72.7% (16/22), and there was no statistical difference between the two groups (x 2=0.231, P0.05) 2.2 stage in 34 cases of stage III - IV ovarian cancer 88.2% (30/34), and 16 cases of stage I - II ovarian cancer, the positive rate of TGF- beta 1 was 50% (8/16), and the difference was statistically significant (chi 2=8.720, P0.05) 2.3. The positive expression rate of TGF- beta 1 in 24 serous cystadenocarcinoma was 79.2% (19/24), and the positive expression rate of TGF- beta 1 in 16 cases of mucinous cystadenocarcinoma was 68.8% (11/16). The positive rate of TGF- beta 1 in 10 cases of ovarian endometrioid carcinoma was 80% (8/10), and there was no significant difference between three (x 2=0.739, P0.05), and 2.4 tissue pathological differentiation was in 24. The positive expression rate of TGF- beta 1 in the high school group was 66.7% (16/24), and the positive expression rate of TGF- beta 1 in 26 low differentiation groups was 84.6% (22/26 case). The two cases had no statistical difference (x 2=2.204, P0.05).2.5 lymph node metastasis in 32 cases of lymph node metastasis group, the positive rate of TGF- beta 1 was 81.3% (26/32 cases), 18 cases had TGF- beta 1 in the lymph node without metastasis group. The positive expression rate was 66.7% (12/18), and there was no statistical difference between the two (x, P0.05).3 TGF- beta 1. The relationship between the expression of MDR1, PTEN, TOPOII, ERCC1, LIVIN resistance genes was positively correlated with the expression of MDR1. There was no correlation between the expression of OPOII (r=-0.506, P=0.078) and the expression of.TGF- beta 1 and ERCC1 (r=-0.037, P=0.636), and there was no correlation between the expression of.TGF- beta 1 and LIVIN (r=-0.801, P=0.21). Conclusion: the positive expression level of 1 TGF- beta 1 in epithelial ovarian cancer is high, and the positive expression level of the benign ovarian tumor and normal ovary is 1. Lower than epithelial ovarian cancer, normal ovarian tissue, benign ovarian tumor, epithelial ovarian cancer, and TGF- beta 1, the expression of TGF- beta 1 in the ovarian tissue from benign to malignant development plays an important role, TGF- beta 1 can be used as a biological indicator for the diagnosis of epithelial oval carcinoma of.2, TGF- beta 1 in ovarian cancer tissue There is no correlation between the age size, the type of histology, the degree of histology, the degree of histopathological differentiation, and the occurrence of lymph node metastasis, but there is a positive correlation with the clinical stages. It shows that the expression of TGF- beta 1 in TGF- beta 1 is positively related to the expression of MDR1 in the epithelial ovarian cancer of ovarian cancer, suggesting that it is in the development of the tumor. .TGF- PTEN 1 is negatively correlated with the expression of PTEN, indicating that they interact with each other.

【学位授予单位】：河北医科大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：R737.31

【参考文献】